A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BIIB104 Test FormulationDrug: BIIB104 Reference Formulation
- Registration Number
- NCT05152485
- Lead Sponsor
- Biogen
- Brief Summary
The primary objectives of this study are to evaluate the relative bioavailability of the BIIB104 test formulation compared with the reference formulation in healthy Caucasian male adult participants in the fasted state and to assess the impact of food on BIIB104 pharmacokinetic (PK) parameters for the test formulation in healthy Caucasian male adult participants.
The secondary objective of the study is to assess the safety and tolerability of BIIB104 0.5 milligrams (mg) test formulation in the fasted and fed states following single-dose administration.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 36
- Has a body mass index (BMI) between 18 and 30 kilogram per square meter (kg/m^2), inclusive and a total body weight >50 kilograms [110 pound (lb)].
Key
- Participates in other studies involving treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to randomization and/or during study participation.
- Previously participated in this study or previous studies with BIIB104.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BIIB104 0.5 mg Test Formulation (Fasted State) BIIB104 Test Formulation Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fasted state. BIIB104 0.5 mg Test Formulation (Fed State) BIIB104 Test Formulation Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fed state. BIIB104 0.5 mg Reference Formulation (Fasted State) BIIB104 Reference Formulation Participants will receive BIIB104 0.5 mg, immediate-release liquid-filled hard-shell capsule, orally, on Day 1 in the fasted state.
- Primary Outcome Measures
Name Time Method Area Under the Plasma Concentration-Time Curve from Time Zero to Time of the Last Measurable Concentration (AUClast) of BIIB104 Up to Day 6 Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf) of BIIB104 Up to Day 6 Maximum Observed Plasma Concentration (Cmax) of BIIB104 Up to Day 6 Time to Reach Maximum Observed Plasma Concentration (Tmax) for BIIB104 Up to Day 6
- Secondary Outcome Measures
Name Time Method Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) From Day 1 up to end of study (up to Day 16) An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are AEs that start or worsen after receiving the study drug. An SAE is any untoward medical occurrence that at any dose results in death; in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event.
Number of Participants with Clinically Significant Abnormalities in Clinical Laboratory Parameters From Day 1 up to end of study (up to Day 16) Number of Participants with Clinically Significant Abnormalities in Vital Signs From Day 1 up to end of study (up to Day 16) Number of Participants with Clinically Significant Abnormalities in Physical Examination Parameters From Day 1 up to end of study (up to Day 16)
Trial Locations
- Locations (1)
QPS MRA
🇺🇸Miami, Florida, United States